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Introduction
The debate regarding surgery on asymptomatic or mildly 
symptomatic patients with aortic valve disease (AVD) is long-
standing.1,2 Brock recommended invasive investigation and 
intervention before the advent of heart failure.3 The median time 
to death with stenosis (AS) is 4.5 years after chest pain, 2.6 years 
after syncope and 1 year after heart failure, with a 5-year survival 
of less than 20%.4 In untreated aortic regurgitation, long-term 
survival is curtailed, especially in patients with reduced functional 
class and elevated end-systolic dimensions.5 Surgery improves 
outcomes even in the setting of left ventricular dysfunction.6 
The increasing incidence of AVD in the elderly population 
renders this condition a significant public-health problem. It 
is against this control group, with up to 12% incidence in the 
over 75’s, that the impact of surgery should be evaluated.7 
When patients die within 30 days of surgery, death is attributed 
to the procedure. However the cause of late death is often 
undetermined because of inaccurate information. The effect of 
surgery on long-term survival may be evaluated in a relative 
survival model.8 This long-term study compares survival after 
aortic valve replacement (AVR) with local age- and gender-
matched controls, providing an estimate of predicted post-
operative life expectancy. 
Patients understand that operative risk is offset by a predicted 
significant survival enhancement with AVR. They also wish 
to know whether surgery can restore normal life expectancy. 
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Abstract
Background 
This 20-year relative survival study investigates life expectancy in defined age cohorts and evaluates the role of patient, procedural 
and peri-operative variables on absolute survival after aortic valve replacement.
Methods  
Absolute long-term survival variance was calculated using Cox regression analysis in 585 consecutive aortic valve replacement 
patients. Relative survival curves in defined age groups were constructed using age- and gender-matched controls. 
Results  
There were 12 peri-operative deaths (2.1%), and 11 further deaths (1.9%) during the first year. 154 patients (26.3%) died 
subsequently and 408 patients (69.7%) were alive after 20 years. Relative survival increased with age: in patients over 68 survival 
was equivalent to an age- and gender-matched population. Patient risk indicators for decreased absolute survival included age, 
Parsonnet score, additive and logistic EuroSCORE, and for increased absolute survival included weight, body surface area, 
and stroke volume. Procedural risk indicators for decreased absolute survival included bypass time, use of a tissue valve, and 
prosthesis-patient mismatch with size 19 valves, and for an increased absolute survival included use of a mechanical valve. Post-
operative risk indicators for decreased absolute survival included ITU stay, ventilation time, transfusion, haemorrhage volume and 
new-onset atrial fibrillation/flutter. Strong risk indicators included intra-aortic balloon pump use, and dialysis. 
Conclusions  
Patients over 68 years discharged from hospital after aortic valve replacement had a similar 10-year survival as an age- and gender-
matched population. In this age cohort surgery restored the patient’s normal life expectancy.
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Long-term survival is determined by post-operative survival, 
the lasting effects of surgery, and continuing medical therapy. 
Survival prediction is meaningful when taken in context with 
local relative survival analysis, incorporating data from national 
life expectancy tables and local post-operative outcome 
data.9 The inclusion of variables other than age and gender 
may further enhance risk-benefit assessment.10 Such analysis 
aids decision making regarding surgery, particularly in elderly 
patients, when individual risk scores are of limited value.9
Methods
Study design
The Ethical Committee of the University of Malta granted 
approval for this study.
585 consecutive patients undergoing AVR, with or without 
concomitant coronary revascularization, between January 1995 
and December 2014, in a single-surgeon practice, were entered 
into the study. Patients requiring combined procedures on the 
mitral valve or the ascending aorta were excluded.
Patients and protocols
All procedures were performed on normothermic 
cardiopulmonary bypass with a membrane oxygenator. 
Myocardial protection was with antegrade St Thomas’ 
cardioplegia prior to May 2006 and subsequently with blood 
cardioplegia. Patients under 70 received a mechanical 
prosthesis, while older patients generally received a xenograft 
unless there were confounding factors. All mechanical valve 
patients were anticoagulated, whereas patients with xenografts 
received aspirin in the absence of a separate indication for 
anticoagulation. Prior to 2002 CarboMedics R-Series® Sorin 
was used for sizes 19 and 21 and the Standard valve for sizes 
23 and 25. Subsequently CarboMedics Top Hat® Sorin was 
used for sizes 19, 21 and 23 while CarboMedics Standard® 
Sorin was used for size 25. Xenografts implanted prior to 2002 
were all Carpentier-Edwards Perimount® except for 11 Toronto 
SPV valves.  Subsequently Sorin Mitroflow® valve was used 
for sizes 19 and 21 and Perimount for sizes 23 and 25. Eleven 
Perceval® Sorin valves were implanted in 2014.
Data collection
Data was collected by the surgeon and entered into an 
electronic database. Patient risk assessment was calculated 
at the preoperative visit, operative parameters were entered 
at the termination of surgery, and in-hospital clinical course 
was completed at the patient’s discharge. Parsonnet risk 
stratification was used from the outset of the study whilst 
additive and logistic EuroSCORE were also used from 2000 
and 2006 respectively. The logistic EuroSCORE for patients 
entered between 2000 and 2006 was calculated retrospectively. 
Data collected prospectively was combined with patient data 
pertaining to survival or date of death derived from the Patient 
Administration System while general population survival data 
was derived from the National Statistics Office database.
Endpoints
Absolute survival after AVR is presented as Kaplan-Meier 
survival curves for four subgroups of the surgical population. 
Hazard ratios were calculated for certain demographic, 
operative and post-operative clinical parameters. Relative 
survival curves relate the post-operative absolute survival 
curves with those of an age- and gender-matched population 
for the matched follow-up year, derived from the National 
Statistics Office database. 
Risk variables
Variables selected for evaluation were categorized according 
to patient characteristics, the procedure, and the in-hospital 
post-operative course. The date of death was recorded but the 
cause not specified. Patient-related variables included age, 
gender, height, weight, body surface area (BSA), body mass 
index (BMI), diabetes, hypertension, Parsonnet score, additive 
and logistic EuroSCORE, and cardiac indices (ejection fraction 
EF, end-diastolic volume EDV, end-systolic volume ESV and 
stroke volume SV). Procedural variables included urgency, 
repeat procedure, ischaemic time, bypass time, mechanical 
valve, tissue valve, concomitant revascularization (+CABG), 
valve stenosis, mixed disease or pure regurgitation, and indexed 
Effective Orifice Area (iEOA). Post-operative variables included 
intensive care (ITU), high dependency (HDU) and step-down 
ward stay, ventilation time, haemorrhage volume, blood 
transfusion, atrial fibrillation or flutter, stroke (CVA) and transient 
ischaemic attack (TIA), and post-operative intra-aortic balloon 
pump (IABP) and dialysis usage.
Relative survival
Relative survival is the ratio of the observed survival to the 
expected survival patients would experience had they been 
exposed only to the survival probabilities of the general 
population (background mortality). The relative survival curves 
compare the absolute survival with an age- and gender-
matched population derived from the National Statistics Office 
database. Differences in mortality vary considerably in the later 
years of life and so life tables truncated at 85+ and 90+ years 
were extended into single year tables up to 100 years of age. 
In the absence of reliable data for Malta, life tables derived 
from England and Wales from 1998 to 2000 were extended 
and smoothed using the Ewbank four parameter method for 
each table by year and gender separately.11 Goodness of fit of 
the derived life tables was assessed by plotting the smoothed 
mortality rates and survivor function in each table against the 
observed mortality rates. Life expectancy as published by the 
Office for National Statistics in Malta is 79.6 for males and 84 
for females (78.7 and 82.6 respectively in England and Wales). 
Analysis was conducted in STATA version 11.
Statistical Methods
Means and standard deviations were used to measure 
central tendency and dispersion for continuous variables 
and frequency tables and crosstabs were used to describe 
categorical variables. Statistical inference was carried 
out using the One-Way ANOVA and Chi square tests. The 
One-Way ANOVA test compares means of patient-related, 
procedural and post-operative continuous variables between 
independent age groups (15-59, 60-67, 68-73 and >74 years). 
The Chi squared test assesses the association between 
patient-related, procedural and post-operative categorical 
variables and age groups. Survival probabilities for the study 
cohort (total population and age specific groups) and the 
age- and gender-matched population were computed using 
the Kaplan-Meier estimate. Cox regression analysis was used 
to relate survival times (follow-up duration) to a number of 
patient-related, procedural and post-operative predictors, 
where the patients who were still alive at the end of the 
investigation period were right censored. The hazard ratios 
and their 95% confidence intervals were computed for each of 
these risk/protective variables.
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Results
Study cohort
585 patients were divided into four age ranges of comparable size 
(groups A-D), as determined by the closest whole year integer 
(table 1). 224 (38.3%) were female, and incidence increased with 
age. All in-hospital deaths (2.1%) were classified as peri-operative 
deaths, even if they occurred after 30 days from surgery. Survivors 
were defined as patients who were discharged from hospital and 
survived surgery beyond 30 days. Amongst survivors the mean 
and maximum follow-up for each group is shown in table 1. The 
mean follow-up was shorter with increasing age, reflecting a trend 
for more surgery in the elderly in recent years. The annualized 
percentage death rate (ADR%) was derived by dividing the 
number of deaths other than peri-operative deaths (expressed as a 
percentage of the group) by the mean follow-up in years.
93% (322/348) patients under 70 received a mechanical valve, 
whereas 95% (226/237) patients over 70 received a tissue valve. 
Concomitant revascularization was highest in group C whilst the 
requirement for urgent surgery was highest in group D (table 2). 
The valve lesion was classified as stenosis, mixed (stenosis and 
regurgitation) or pure regurgitation. The incidence of combined 
stenosis and mixed valve disease increased with age, whereas 
pure regurgitation was rare (<4%) in group D. Risk stratification 
score increased with age, with a significant increment in Parsonnet 
in the over 70’s and a similar increment in the EuroSCORE in the 
over 60’s, in-keeping with the weighting design of these systems. 
Absolute survival
The mean follow-up in survivors was 8.2 years (median 7.6 
years). The follow-up period was 20 years and during this 
time 407 patients were censored and 178 patients died. There 
were 12 peri-operative deaths (2.1%), 4 deaths in the valve 
replacement only group (1.0%, n=386) and 8 in the valve 
replacement + CABG group (4.0%, n=199). The predicted 
mortality for the whole group was 5.2% by additive EuroSCORE 
and 4.9% by logistic EuroSCORE. Another 11 patients (1.9%) 
died within the first year after surgery and a further 154 (26.3%) 
died beyond the first year. 408 patients (69.7%) were alive at 
the end of the 20-year follow-up period. The absolute survival 
Kaplan-Meier curves for the entire study group as well as for the 
age-defined sub-groups are presented in figure 1.
The risk indicators for the sub-groups A to D are presented in 
table 3. A hazard ratio (HR) above 1.0 ascribes an increased 
propensity for an event in the presence of certain variables, 
categorized as patient variables, procedure variables and post-
operative variables, while a hazard ratio below 1.0 ascribes a 
protective factor (tables 4 and 5).
Patient variables
Four patient risk indicators for a decreased absolute survival 
included age (HR 1.077, 95% CI 1.058-1.096, p<0.001), 
Parsonnet score (HR 1.084, 95% CI 1.064-1.104, p<0.001), 
additive EuroSCORE (HR 1.244, 95% CI 1.152-1.343, p<0.001), 
and logistic EuroSCORE (HR 1.046, 95% CI 1.017-1.077, 
p=0.002). Three patient protective variables for absolute survival 
included weight (HR 0.979, 95% CI 0.964-0.994, p=0.008), BSA 
(HR 0.290, 95% CI 0.104-0.810, p=0.018), and SV (HR 0.992, 
95% CI 0.983-0.999, p=0.041). 
Procedural variables
Four procedural risk indicators for a decreased absolute survival 
included bypass time (HR 1.018, 95% CI 1.008-1.028, p=0.001), 
the use of a tissue valve (HR 2.648, 95% CI 1.931-3.630, 
p<0.001), combined tissue valve and CABG (HR 2.150, 95% CI 
1.508-3.064, p<0.001) and prosthesis-patient mismatch for size 
19 valves (HR 1.127, 95% CI 1.034-1.228, p=0.006). A strong 
procedural protective variable for absolute survival included 
the use of a mechanical valve (HR 0.302, 95% CI 0.210-0.433, 
p<0.001) and combined mechanical valve and CABG (HR 0.284, 
95% CI 0.209-0.385, p<0.001).
Table 1. Peri-operative and late deaths
age group n F% peri-op death30dy-1yr > 1yr
follow-up (yr)
mean±SD max ADR%  
A 15-59 149 24.8 1 3 19 11.3±5.2 20.0 1.31%
B 60-67 147 34.0 2 2 39 8.4±5.6 19.0 3.32%
C 68-73 152 42.8 5+ 3 49 7.2±5.2 18.8 4.75%
D >74 137 52.6 4* 3 47 4.5±3.9 16.8 8.11%
Legend: ADR%: annualised percentage death rate 
F%: percentage female +includes one in-hospital death at 30 days  *includes one in-hospital death at 117 days
Table 2. Pathology and risk stratification
n +CABG (%) urgent % AS/M% Parsonnet Euro SCORE*additive Logistic
A  15-59 149 35 (23.5)   9.4 83.3   8.87 ± 3.60 2.99 ± 1.32 2.47 ± 1.90
B  60-67 147 53 (36.1)   7.5 91.1   9.71 ± 4.17 4.34 ± 1.32 3.21 ± 1.92
C  68-73 152 58 (38.2)   8.6 92.5 14.52 ± 4.81 5.78 ± 1.31 5.20 ± 4.04
D   >74 137 48 (35.0) 24.1 96.5 23.12 ± 5.20 7.33 ± 1.33 8.08 ± 3.82
Legend: +CABG: concomitant revascularisation AS/M: pure aortic stenosis or mixed aortic valve disease *calculated from 2000 
onwards, n=453
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Table 3. Risk indicators for age groups
149 patients 147 patients 152 patients 137 patients
15-59 years 60-67 years 68-73 years >74 years
n(%)/m(SD) n(%)/m(SD) n(%)/m(SD) n(%)/m(SD) p value
Patient Characteristics
age 49.6 (8.99) 63.5 (2.32) 70.3 (1.72) 77.7 (3.02) <0.001
gender(female) 37 (24.8%) 50 (34.0%) 65 (42.8%) 72 (52.6%) <0.001
outcome (died) 22 (14.8%) 43 (29.3%) 57 (37.5%) 54 (39.4%) <0.001
operative death 1 (0.7%) 2 (1.4%) 5 (3.3%) 4 (2.9%)   0.329
time to death (yr) 7.1 (4.90) 7.8 (4.72) 7.5 (4.83) 6.6 (4.36)   0.605
height(m) 1.63 (0.10) 1.60 (0.09) 1.55 (0.21) 1.55 (0.10) <0.001
weight(kg) 79.4 (15.9) 78.9 (14.2) 73.0 (12.8) 70.8 (13.3) <0.001
BSA(m2) 1.96 (1.40) 1.82 (0.19) 1.74 (0.18) 1.70 (0.19)   0.017
BMI(kg/m2) 29.8 (5.49) 30.7 (5.06) 29.3 (4.30) 29.4 (5.06)   0.097
diabetes 12 (8.1%) 23 (15.6%) 30 (19.7%) 34 (24.8%)   0.130
hypertension 26 (17.4%) 50 (34.0%) 54 (35.5%) 67 (48.9%)   0.014
Parsonnet 8.9 (3.60) 9.7 (4.17) 14.5 (4.81) 23.1 (5.20) <0.001
EuroSCORE(add) 3.0 (1.32) 4.3 (1.32) 5.8 (1.31) 7.3 (1.33) <0.001
EuroSCORE(log) 2.5 (1.90) 3.2 (1.92) 5.2 (4.04) 8.1 (3.82) <0.001
EF(%) 66.6 (14.9) 69.1 (13.6) 72.1 (15.0) 71.7 (12.6)   0.390
EDV(ml) 135.6 (32.4) 143.4 (61.9) 148.8 (51.1) 141.8 (49.9)   0.783
ESV(ml) 45.3 (22.3) 44.3 (36.2) 41.5 (29.4) 40.2 (29.9)   0.902
SV(ml) 90.3 (31.1) 99.1 (34.4) 107.3 (43.3) 101.6 (27.7)   0.370
Procedural Variables
urgent/emergency 16 (10.7%) 12 (8.2%) 14 (9.2%) 35 (25.5%) <0.001
redo 7 (4.7%) 3 (2.0%) 3 (2.0%) 2 (1.5%)   0.289
ischaemia(min) 56.8 (14.6) 57.9 (14.1) 57.5 (11.1) 58.1 (12.4)   0.903
bypass(min) 69.5 (20.7) 71.5 (19.0) 72.5 (17.8) 71.8 (16.9)   0.679
mech±CABG 148 (99.3%) 137 (93.2%) 46 (30.3%) 3 (2.2%) <0.001
mechanical 113 (75.8%) 83 (56.5%) 24 (15.8%) 2 (1.5%) <0.001
mech+CABG 35 (23.5%) 54 (36.7%) 22 (14.5%) 1 (0.7%) <0.001
tissue±CABG 1 (0.7%) 10 (6.8%) 106 (69.7%) 134 (97.8%) <0.001
tissue 1 (0.7%) 8 (5.4%) 68 (41.4%) 87 (63.5%) <0.001
tissue+CABG 0 (0.0%) 2 (1.4%) 38 (25.0%) 47 (34.3%) <0.001
stenosis/ mixed 121 (81.3%) 133 (90.7%) 140 (92.2%) 131 (95.6%)   0.002
regurgitation 28 (18.7%) 14 (9.3%) 12 (7.8%) 6 (4.4%)   0.002
Indexed EOA
19 0.63 (0.06) 0.66 (0.05) 0.72 (0.12) 0.78 (0.05) <0.001
21 0.87 (0.09) 0.85 (0.09) 0.84 (0.10) 0.82 (0.09)   0.141
23 1.04 (0.10) 1.06 (0.10) 1.03 (0.12) 0.97 (0.12)   0.003
25 1.05 (0.12) 1.05 (0.12) 1.02 (0.11) 0.95 (0.21)   0.045
all sizes 0.98 (0.16) 0.97 (0.15) 0.93 (0.15) 0.88 (0.14) <0.001
Post-operative Variables
ITU(dy) 1.18 (1.40) 1.07 (0.52) 1.36 (1.94) 1.96 (9.86)   0.445
HDU(dy) 1.71 (3.02) 1.48 (2.09) 1.54 (1.72) 2.53 (4.12)   0.030
ward(dy) 3.42 (3.10) 3.57 (2.40) 3.76 (2.77) 5.34 (5.71) <0.001
ventilation(hr) 12.2 (40.1) 9.4 (8.6) 12.8 (35.8) 16.2 (51.9)   0.617
transfusion(unit) 0.92 (2.56) 0.86 (1.60) 1.14 (1.89) 1.77 (2.92)   0.026
haemorrhage(ml) 412.8 (301.1) 437.8 (345.7) 498.4 (316.8) 480.9 (321.2)   0.181
IABP 6 (4.0%) 4 (2.7%) 8 (5.3%) 4 (2.9%)   0.641
atrial fib/flutter 19 (12.8%) 39 (26.5%) 36 (23.7%) 51 (37.2%) <0.001
dialysis 3 (2.0%) 4 (2.7%) 5 (3.3%) 12 (8.8%)   0.009
CVA/TIA 2 (1.3%) 4 (2.7%) 3 (2.0%) 2 (1.5%)   0.817
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Table 4.  Cox regression (Univariate Analysis)
n(%)/ m(SD) Hazard Ratio (95%) CI of HR p value
patient characteristics
age 65.1 (11.4) 1.077 1.058 – 1.096 <0.001
gender(female) 224 (38.3%) 1.068 0.789 – 1.445   0.671
height(m) 1.59 (0.10) 0.191 0.025 – 1.474   0.112
weight(kg) 76.1 (15.1) 0.979 0.964 – 0.994   0.008
BSA(m2) 1.82 (0.83) 0.290 0.104 – 0.810   0.018
BMI(kg/m2) 30.0 (5.20) 0.968 0.929 – 1.009   0.129
diabetes 99 (16.9%) 1.318 0.714 – 2.433   0.377
hypertension 197 (33.7%) 1.546 0.791 – 3.021   0.203
Parsonnet 13.9 (7.13) 1.084 1.064 – 1.104 <0.001
EuroSCORE(add) 5.23 (2.09) 1.244 1.152 – 1.343 <0.001
EuroSCORE(log) 4.91 (3.85) 1.046 1.017 – 1.077   0.002
EF (%) 69.9 (13.8) 0.988 0.971 – 1.005   0.166
EDV(ml) 142.4 (51.6) 0.996 0.990 – 1.001   0.093
ESV(ml) 42.9 (30.7) 1.002 0.994 – 1.009   0.675
SV(ml) 99.6 (36.9) 0.992 0.983 – 0.999   0.041
procedural variables
urgent/emergency 77 (13.2%) 1.384 0.918 – 2.087   0.120
redo 15 (2.6%) 1.018 0.451 – 2.300   0.965
ischaemia(min) 57.6 (13.0) 1.012 0.997 – 1.026   0.108
bypass(min) 71.4 (18.6) 1.018 1.008 – 1.028   0.001
mech±CABG 334 (57.1%) 0.284 0.209 – 0.385 <0.001
mechanical 222 (37.9%) 0.302 0.210 – 0.433 <0.001
mech+CABG 112 (19.1%) 0.831 0.576 – 1.199   0.321
tissue±CABG 251 (42.9%) 3.437 2.532 – 4.664 <0.001
tissue 164 (28.0%) 2.648 1.931 – 3.630 <0.001
tissue+CABG 87 (14.9%) 2.150 1.508 – 3.064 <0.001
stenosis/ mixed 283 (48.4%) 0.872 0.721 – 1.056   0.161
regurgitation 46 (7.9%) 0.704 0.372 – 1.331   0.280
indexed EOA
19 0.72 (0.10) 1.127 1.034 – 1.228   0.006
21 0.84 (0.09) 1.011 0.987 – 1.036   0.365
23 1.03 (0.11) 0.987 0.965 – 1.010   0.268
25 1.02 (0.14) 0.988 0.973 – 1.004   0.148
all sizes 0.94 (0.16) 0.999 0.990 – 1.008   0.827
post-operative variables
ITU(dy) 1.38 (4.95) 1.039 1.024 – 1.053 <0.001
HDU(dy) 1.83 (2.92) 1.046 0.984 – 1.111   0.150
ward(dy) 4.00 (3.76) 1.071 1.042 – 1.101   0.150
ventilation(hr) 12.8 (38.3) 1.010 1.007 – 1.013 <0.001
transfusion(unit) 1.21 (2.34) 1.213 1.155 – 1.273 <0.001
haemorrhage(ml) 459.8 (322.2) 1.001 1.000 – 1.002   0.002
IABP 22 (3.8%) 4.567 2.458 – 8.483 <0.001
atrial fib/flutter 145 (24.8%) 1.618 1.147 – 2.281   0.006
dialysis 24 (4.1%) 8.737 4.942 – 15.45 <0.001
CVA/TIA 11 (1.9%) 1.120 0.357 – 3.507   0.846
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Post-operative variables
Post-operative risk indicators for a decreased absolute 
survival included ITU length of stay (HR 1.039, 95% CI 
1.024-1.053, p<0.001), ventilation time (HR 1.010, 95% CI 
1.007-1.013, p<0.001), blood transfusion (HR 1.213, 95% CI 
1.155-1.273, p<0.001), haemorrhage volume (HR 1.001, 95% 
CI 1.000-1.002, p=0.002) and new-onset atrial fibrillation or 
flutter (HR 1.618, 95% CI 1.147-2.281, p=0.006). Very strong 
risk indicators included the use of IABP (HR 4.567, 95% CI 
2.458-8.483, p<0.001), and of dialysis (HR 8.737, 95% CI 
4.942-15.45, p<0.001). When these predictors were analyzed 
collectively (multivariate analysis), the Cox regression model 
identified four significant predictors for a decreased absolute 
survival: Parsonnet score, ITU stay, ward stay and haemorrhage 
volume (table 5).
Relative survival
Patients included in this analysis (n=524) underwent surgery 
up to 2013 to allow for a minimum follow-up of a year. Relative 
survival curves were plotted by age groups and follow-up time 
was truncated at the point where less than 50 patients remained 
at risk. 
Figure 2 shows the survival curve with 95% confidence intervals 
for the total population. The one-year relative survival probability 
(98.2%, 95% CI 96.0-99.6) was slightly lower in the first year 
than the survival expected in age- and gender-matched counter 
parts. However the 5-year (99.3%, 95% CI 95.5-102.4) and 
10 year survival probability (98.1%, 95% CI 91.7-104.5) show 
similar survival. Relative survival hazard was significantly lower 
in groups B, C and D when compared with group A (figure 3). 
Analysis by age groups was performed for the four age groups 
and also for two amalgamated age groups (15-67 and 68+) to 
allow for more robust analysis (figure 2). Survival in the15-67 
age group remains lower than the age- and gender-matched 
general population over the 10 years of follow up (upper CI does 
not surpass 1). For those aged 68+ no difference in survival 
was noted for age- and gender-matched counterparts except 
at the fourth year of follow up where patients showed a higher 
survival probability (106%, 95% CI 100.6-110.3). In spite of 
wider confidence intervals with increasing follow-up, the data 
suggests that survival in the 68+ group is better than that in the 
younger age group.
Table 5. Cox regression (Multivariate Analysis)
m(SD) Hazard Ratio
95%) CI  
of HR p value
patient characteristics
Parsonnet 13.9  (7.13) 1.057
1.019 –  
1.097   0.003
post-operative variables
ITU(dy) 1.38  (4.95) 1.364
1.218 –  
1.527 <0.001
ward(dy) 4.00  (3.76) 1.129
1.069 –  
1.193 <0.001
haemorrhage(ml) 459.8 
(322.2) 1.001
1.000 –  
1.002   0.031
Figure 1. Kalpan-Meier absolute survival curves for whole study 
population and for four age cohorts. For univariate analysis, the 
Cox regression model identified the following strong predictors 
of survival times:
Figure 2. Relative survival curves for whole study population 
and for two amalgamated age cohorts. Population at risk: upper 
figures groups C+D, lower figures groups A+B.
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Discussion
Findings and Data interpretation
A higher risk stratification score predicted an increased 
propensity for reduced long-term survival. Although the 
additive and logistic EuroSCORE have superseded the older 
Parsonnet system, the latter remained the strongest indicator 
for long-term survival when subjected to multivariate analysis. 
Parsonnet score is a reliable predictor of intensive care stay 
and of complications including intra-aortic balloon pump use 
and renal replacement therapy, variables that strongly predicted 
long-term outcome in our study.12 Despite its shortcomings in 
over-predicting operative mortality, Parsonnet remains a simple 
and useful predictor of long-term survival after AVR.
Despite the guarded prognosis associated with pure aortic 
regurgitation reported in previous studies, our results do not 
support this variable as a significant risk predictor of decreased 
long-term survival.2,13 Confounding factors in our study include 
a preserved EF of 65.1±15.8% (75% had an EF >55%) in spite 
of a significantly increased left ventricular end-systolic volume 
of 66.5±41.1ml as calculated at ventriculography, suggesting 
that surgery was performed expeditiously. The small numbers in 
the elderly subgroup may pose a further study limitation.
The effect of prosthesis-patient mismatch (PPM) on long-term 
survival was evaluated by using the indexed Effective Orifice 
Area (EOA) for each size category and for the entire group. An 
indexed EOA of ≤ 0.85cm2/m2 defined moderate PPM and ≤ 
0.65cm2/m2 defined severe PPM. The EOA’s for the valves were 
obtained from independent researchers and derived from in vivo 
studies.14,15 Data was available on 565 patients and their valves, 
of which 71% had no PPM. There were 10 cases of severe 
PPM, all in patients receiving size 19 valves and 156 cases of 
mild PPM (33 in size 19, 111 in size 21, 8 in size 23 and 4 in size 
25). Ninety-three cases of moderate PPM occurred in patients 
over 70 receiving a xenograft, in whom a presumed relatively 
curtailed activity would reduce the impact of trans-valvular flow 
on trans-valvular pressure gradient. Our incidence of mismatch 
is lower than that quoted in other series using the same 
criteria.16,17 For size 19 valves, mismatch impacted negatively 
on long-term survival, with mortality increasing by 12.7% when 
compared with the other sizes, suggesting that valve size was a 
more important predictor than valve type or model. Mismatch in 
larger sizes had no significant impact on long-term survival.
Peri-operative transfusion has been shown independently to 
double 5-year mortality after cardiac surgery. We demonstrated 
a similar trend after AVR. Blood was administered more 
frequently in older and smaller patients, variables associated 
with a decreased long-term survival in our study.18,19  
New-onset atrial fibrillation or flutter increased with age and was 
a significant predictor of reduced long-term survival (HR 1.618). 
This is in keeping with a similar study by Filardo et al, citing an 
HR of 1.48.20
The strongest post-operative indicator for a poor long-term 
outcome was renal dialysis (HR 8.737), also reported in a 
previous study,10 followed by IABP usage (HR 4.567), which has 
been reported to affect both early and late mortality after AVR.21 
Other significant variables, reported in previous studies, were 
not analysed in our study due to a very low incidence. Thus 
Lassnigg et al reported an HR of 1.8 for resternotomy, which 
occurred in 9.36% of cases (173/1848 patients) whilst our 
incidence was significantly less at 2.05% (p<0.0001). Similarly 
our incidence of reoperation was 2.56%, compared with 
Lassnigg’s 9.90%.10
The newer alternative therapy of transcatheter aortic valve 
implantation (TAVI) may significantly impact the long-term 
survival of patients with aortic valve disease.22 Although patients 
were increasingly treated by this method in Malta since 2010, 
these were not included in this study.
Clinical implications
This study demonstrates multiple variables that impacted 
absolute long-term survival. Size 19 valves reduced long-term 
survival, as did blood transfusion, highlighting the importance 
of strategies that reduce its requirement. We have shown that in 
patients aged over 68 years, relative survival was comparable 
to age- and gender-matched controls. Other investigators 
have emphasized the importance of additional clinical features 
including severe valve calcification,23 a jet velocity of >4m/s,24 
and of a positive stress test25 in helping the surgeon reach 
a decision regarding surgery. All patients in our study had 
symptomatic aortic valve disease. Previous series that also 
included asymptomatic patients with severe AS demonstrated 
a lower operative mortality and a long-term survival similar to 
that in symptomatic patients and comparable to an age- and 
gender-matched control population.26 This data is important 
when making a decision regarding AVR, especially in the 
absence of symptoms. Our results and those of other groups 
would favor a policy of considering all patients with severe AS 
for surgery, irrespective of symptoms. 
Figure 3. Relative survival curves for four age cohorts, including 
population at risk.
Original Article | 53International Cardiovascular Forum Journal 6 (2016)DOI: 10.17987/icfj.v6i0.138
Limitations
Since variables included in this retrospective study where 
those that were collected after 1995, other, possibly relevant, 
confounding factors may have been omitted. Our cardiac unit 
is the only one serving the local population and protocols and 
methods may be at variance with other foreign units, limiting its 
value with regard to generalizations. This study analysed overall 
survival and non-cardiac causes of mortality may have obscured 
the results, especially in older cohorts. Nevertheless the model 
of relative survival is designed to take this factor into account 
and to yield valuable data predicting life expectancy. A possible 
limitation from reliance on foreign life tables in the absence of 
reliable local data pertaining to differences in mortality in the very 
elderly was mitigated by goodness of fit analysis. 
Conclusions
Certain risk predictors affect absolute long-term survival after 
AVR. Although absolute survival is shorter in older patients, 
increasing age had an incrementally smaller negative impact 
on relative survival such that patients over 68 years enjoyed 
a normal life expectancy after surgery. These findings provide 
important additional data when weighing up the risks and 
benefits of surgery for AVD.
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